Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation: Impact of Diabetes

Overview

Journal Am J Cardiovasc Dis

Specialty Cardiology & Vascular Diseases

Date 2021 Dec 1

PMID 34849288

Authors

Ruxandra-Nicoleta Horodinschi

Camelia Cristina Diaconu

Affiliations

Soon will be listed here.

Abstract

Introduction: The objective of our study was to evaluate the severity of diastolic dysfunction in patients with heart failure with preserved ejection fraction (HFpEF), atrial fibrillation (AF) and type 2 diabetes mellitus (T2DM) compared to those with HFpEF and AF without DM.

Material And Methods: This is an observational, prospective, case-control study. We selected 720 patients with heart failure consecutively admitted between March 2019-December 2020, of whom 253 patients with AF. After applying the inclusion/exclusion criteria, 105 subjects remained in the study. The patients were divided into two groups, according to the presence of T2DM: group A (39 patients with T2DM, 37.14%), group B (66 patients without T2DM, 62.85%). 2D transthoracic echocardiography was performed in all patients. The study was approved by the Ethics Committee of the hospital. Statistical analysis was performed using R software, version 4.0.2.

Results: Patients with HFpEF, AF, and T2DM had higher LV filling pressures compared to those without DM (OR = 5.00, 95% CI: 1.77-15.19). Moreover, patients with insulin-requiring T2DM (OR = 6.25, 95% CI: 1.50-25.98) had higher LV filling pressures than those treated with oral antidiabetic drugs (OR = 4.44, 95% CI: 1.37-15.17). We demonstrated that patients with T2DM had higher E/e' ratio (difference -2.78, P 0.0003, 95% CI: -4.24 to -1.31) and lower deceleration time (DT) (difference 23.04, P 0.0002, 95% CI: 11.10-34.97) than those without T2DM.

Conclusions: Patients with HFpEF, AF and T2DM have higher LV filling pressures than those without T2DM, suggesting that the presence of T2DM leads to a more severe diastolic dysfunction.

References

Klapholz M, Maurer M, Lowe A, Messineo F, Meisner J, Mitchell J . Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004; 43(8):1432-8. DOI: 10.1016/j.jacc.2003.11.040. View

Nieminen M, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V . EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27(22):2725-36. DOI: 10.1093/eurheartj/ehl193. View

Lam C . Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res. 2015; 12(4):234-8. DOI: 10.1177/1479164115579006. View

Liu J, Palmieri V, Roman M, Bella J, Fabsitz R, Howard B . The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol. 2001; 37(7):1943-9. DOI: 10.1016/s0735-1097(01)01230-x. View

Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly K . Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Can J Cardiol. 2018; 34(5):632-643. DOI: 10.1016/j.cjca.2018.02.026. View

Kearney M . Chronic heart failure and type 2 diabetes mellitus: The last battle?. Diab Vasc Dis Res. 2015; 12(4):226-7. DOI: 10.1177/1479164115590324. View

Kristensen S, Mogensen U, Jhund P, Petrie M, Preiss D, Win S . Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved.... Circulation. 2017; 135(8):724-735. DOI: 10.1161/CIRCULATIONAHA.116.024593. View

Otsuka T, Suzuki M, Yoshikawa H, Sugi K . Left ventricular diastolic dysfunction in the early stage of chronic kidney disease. J Cardiol. 2009; 54(2):199-204. DOI: 10.1016/j.jjcc.2009.05.002. View

Arques S . Clinical Relevance of the Spectral Tissue Doppler E/e' Ratio in the Management of Patients with Atrial Fibrillation: a Comprehensive Review of the Literature. J Atr Fibrillation. 2018; 11(2):2038. PMC: 6244300. DOI: 10.4022/jafib.2038. View

10.

Paulus W, Tschope C . A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013; 62(4):263-71. DOI: 10.1016/j.jacc.2013.02.092. View

11.

Kishi S, Gidding S, Reis J, Colangelo L, Venkatesh B, Armstrong A . Association of Insulin Resistance and Glycemic Metabolic Abnormalities With LV Structure and Function in Middle Age: The CARDIA Study. JACC Cardiovasc Imaging. 2016; 10(2):105-114. DOI: 10.1016/j.jcmg.2016.02.033. View

12.

Bozkurt B, Coats A, Tsutsui H, Abdelhamid C, Adamopoulos S, Albert N . Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal.... Eur J Heart Fail. 2021; 23(3):352-380. DOI: 10.1002/ejhf.2115. View

13.

Lindman B, Davila-Roman V, Mann D, McNulty S, Semigran M, Lewis G . Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014; 64(6):541-9. PMC: 4133145. DOI: 10.1016/j.jacc.2014.05.030. View

14.

Zhang L, Liebelt J, Madan N, Shan J, Taub C . Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction. Am J Cardiol. 2017; 119(11):1815-1820. DOI: 10.1016/j.amjcard.2017.03.005. View

15.

Teupe C, Rosak C . Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation. Diabetes Res Clin Pract. 2012; 97(2):185-94. DOI: 10.1016/j.diabres.2012.03.008. View

16.

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

17.

Campbell R, Jhund P, Castagno D, Hawkins N, Petrie M, McMurray J . What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. J Am Coll Cardiol. 2012; 60(23):2349-56. DOI: 10.1016/j.jacc.2012.04.064. View

18.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

19.

Westerman S, Wenger N . Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev. 2018; 15(2):136-144. PMC: 6520576. DOI: 10.2174/1573403X15666181205110624. View

20.

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View